EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

PKM2-Mediated Glycolytic Reprogramming in Thyroid Cancer: Mechanistic Insights and Therapeutic Potential

Shenshen Li iD, Wei Liu, Jiaojiao Zheng, Lingyu Ren, Changhao Zhou iD, Qiao Wu iD, Zhilong Ai

Molecules · 25.05.2026 · 31 (11) · 1811

DOI: 10.3390/molecules31111811 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecules, online erschienen am 25.05.2026. Verfasst von Shenshen Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery (Thyroid & Breast), Zhongshan Hospital, Fudan University, Shanghai 200030, China. Hauptthemen laut MEDLINE: Glycolysis, Metabolic Reprogramming, Thyroid Neoplasms, Pyruvate Kinase. Die Arbeit nennt 155 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shanghai Innovation Medical Device Application Demon- stration Project 2023, Zhongshan Hospital, Shanghai Innovation Medical Device Application Demonstration Project 2023.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Thyroid cancer (TC) is an endocrine malignant tumor with the fastest-growing incidence worldwide. It has complex pathological types and significant heterogeneity, with great differences in clinical prognosis among different subtypes. Among them, aggressive subtypes, such as radioiodine-refractory (RAI-R) TC and anaplastic thyroid cancer (ATC), have become a major challenge in current clinical diagnosis and treatment, due to limited treatment options and high risks of recurrence and metastasis. Tumor metabolic reprogramming is one of the characteristics of cancer, among which the Warburg effect plays a driving role. As a rate-limiting enzyme in the glycolytic pathway, pyruvate kinase M2 (PKM2), with its unique functional plasticity, has become a linchpin of glycolytic metabolism and malignant phenotypes of tumor cells. This article will systematically review the functional regulatory mechanisms of PKM2, its specific role in TC, and explore the targeted therapeutic strategies and research prospects of TC with PKM2, providing a new theoretical basis and potential plans for the clinical diagnosis and treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlycolysisMetabolic ReprogrammingThyroid NeoplasmsPyruvate KinaseAnimalsHumans

Stichwörter der Autor:innen

PKM2metabolic reprogrammingthyroid cancer

Substanzen

PKM2 protein, humanPyruvate Kinase

Autor:innen und Institutionen

  • Department of Surgery (Thyroid & Breast), Zhongshan Hospital, Fudan University, Shanghai 200030, China.
  • School of Basic Medical Sciences, Fudan University, Shanghai 200433, China.

ORCID-Profile: Shenshen Li, Changhao Zhou, Qiao Wu

Förderung

  • Shanghai Innovation Medical Device Application Demon- stration Project 2023
  • Zhongshan Hospital
  • Shanghai Innovation Medical Device Application Demonstration Project 2023
  • Scientific Research Development Fund of Zhongshan Hospital, Fudan University

Zitieren

APA

Li, S., Liu, W., Zheng, J., Ren, L., Zhou, C., Wu, Q., & Ai, Z. (2026). PKM2-Mediated Glycolytic Reprogramming in Thyroid Cancer: Mechanistic Insights and Therapeutic Potential. Molecules, 31(11), 1811. https://doi.org/10.3390/molecules31111811

Vancouver

Li S, Liu W, Zheng J, Ren L, Zhou C, Wu Q, et al. PKM2-Mediated Glycolytic Reprogramming in Thyroid Cancer: Mechanistic Insights and Therapeutic Potential. Molecules. 2026;31(11):1811. doi:10.3390/molecules31111811

BibTeX
@article{Li2026,
  author = {Li, Shenshen and Liu, Wei and Zheng, Jiaojiao and Ren, Lingyu and Zhou, Changhao and Wu, Qiao and Ai, Zhilong},
  title = {PKM2-Mediated Glycolytic Reprogramming in Thyroid Cancer: Mechanistic Insights and Therapeutic Potential},
  journal = {Molecules},
  year = {2026},
  volume = {31},
  number = {11},
  pages = {1811},
  doi = {10.3390/molecules31111811}
}
Kostenlos starten →